Crossmark Global Holdings Inc. lifted its stake in DaVita Inc. (NYSE:DVA - Free Report) by 19.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 36,769 shares of the company's stock after purchasing an additional 6,000 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in DaVita were worth $5,625,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. increased its position in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after acquiring an additional 76 shares in the last quarter. Copia Wealth Management acquired a new stake in shares of DaVita during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of DaVita during the fourth quarter valued at approximately $41,000. Coppell Advisory Solutions LLC raised its holdings in shares of DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after acquiring an additional 100 shares during the period. Finally, Canada Post Corp Registered Pension Plan acquired a new stake in shares of DaVita during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 90.12% of the company's stock.
DaVita Stock Down 1.2%
DVA traded down $1.79 on Wednesday, reaching $142.01. 810,104 shares of the company traded hands, compared to its average volume of 809,786. The stock's 50 day moving average price is $140.15 and its 200-day moving average price is $149.16. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The company has a market cap of $10.72 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.99 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm's revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.26 earnings per share. On average, sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.
Analysts Set New Price Targets
DVA has been the topic of a number of recent analyst reports. Truist Financial cut their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday, May 19th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $164.50.
Get Our Latest Report on DaVita
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Stories

Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.